{
  "docId": "019dd923-5f69-752d-a9b7-cb9ca917cc95",
  "docSlug": "RKx0dsiKeHCYSDIkE7uF",
  "documentTitle": "Cyclica is already using AI to discover new medicines based on psychedelics. Here's the presentation the biotech startup used to raise a fresh $17 million.",
  "authorId": "Pitchdecks",
  "authorName": "Cyclica",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.78,
  "pageNumber": 4,
  "pageCount": 10,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The diagram illustrates the progression from a drug molecule to a target, then to off-target interactions within a cell, and finally to systemic side-effects.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "process_diagram"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b7-cb9ca917cc95/4",
  "deckHref": "/decks/019dd923-5f69-752d-a9b7-cb9ca917cc95",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b7-cb9ca917cc95.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b7-cb9ca917cc95#slide-4",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Polypharmacology recognizes that therapeutic activity occurs via the modulation of multiple targets.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-a28e-768f-b415-f1b9c2f3eb2a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.9,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "diagram",
      "text": "Visual flow from drug molecule to on-target, off-target, and side-effect outcomes.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e4d554f-68b6-4d21-82cd-fd5be1524d73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Polypharmacology recognizes that therapeutic activity occurs via the modulation of multiple targets. Our appreciation of polypharmacology drives the design and characterization of safer and more efficacious molecules, increasing the likelihood of a drug's downstream success.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8c59942-8296-4425-8e23-d93ba143e40a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "title",
      "text": "Most AI companies are focused on the \"one target, one drug\" paradigm and do not consider the impact of off-target interactions. We are focused on a drug's polypharmacology.",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70a2a347-c5cf-4281-9f74-ddaff9d10888",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "e6b80d98-f6f3-48ec-a502-a7936cd10702",
      "evidence": "Contrasts the industry standard (one target) with the company's superior approach (polypharmacology).",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 4,
      "from": 3,
      "beatId": "959d037a-0be6-422b-9c15-0c1cb408b95d",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "Slides 3-4 discuss the limitations of traditional AI in drug discovery companies.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 5,
      "from": 4,
      "beatId": "b36586bb-3d48-49ef-abf5-7c995f9584a4",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 4-5 present Cyclica's platform and its capabilities.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6deaf774-516a-46da-9cd4-8fce54352f51",
      "evidence": "The document implies that traditional AI in drug discovery companies are limited, and Cyclica's platform offers a more comprehensive solution.",
      "position": 0,
      "objective": "What is the cost of not adopting a more holistic approach to drug discovery?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}